1Biellack SS, Ertmann R, Kempf BB, et al. Impact of scheduling on toxicitvand clinical efficacy of doxorubicin: what do we know in the mid-nineties? Eur J Cancer, 1996,32A(8): 1652-1660
2Legha SS, Benjamin RS, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Am Intern Med, 1982,96( 1 ): 133-139
3Shapira J, Gotfried M, Lishner M, et al. Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen prospective randomized evalnation. Cancer, 1990,65(4) :870-873
4Torti FM,Bristow MR, Howes AE, et al. Reduced cardiotoxicity of doxorubicindelivered on a weekly schedule: assessment by endornycardial biopsy. Ann Intern Med, 1983,99 (4): 745-749
5山本升.ガん化学疗法の副作用对と策初版东京中外医学社,1998.140
6Raymond E. Chemoprotectors: mechanisms of action and clinical applications. Rev Med Intern, 1996,17( 11 ): 936-944
7Dobric S, Dragojevic-Simic V, Bokonjic D, et al. The efficacy of selenium, WR-2721, and their combination in the prevention of adriamycin-induced cardiotoxicity in rats. J Environ Pathol Toxicol Oncol, 1998,17 (3-4): 291-299
8Dorr RT,Lagel K, McLean S. Cardioprotection of rat heart myocytes with amifosme (Ethyol) and its free thiol, WR-t065, int vitro. Eur J Cancer, 1996,32(supp14): S21-25
9Speyer JM, Michael DG. ICRF-187 permits longer treatmet withdoxorubicin in women with breast cancer. J Clin Oncol, 1992, 10(1):117-127
10Wexler LH, Andrich MP, Venzon D, et al. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol, 1996,14 ( 3 ): 362-372
二级参考文献1
1R. P. Abratt,P. A. Willcox,R. H. Hewitson. Etoposide combination therapy for small cell carcinoma of the lung[J] 1987,Cancer Chemotherapy and Pharmacology(1):83～84
2Bryant J, Picot JL, Baxter L. Use of cardiac markers to assess the toxic effects of anthracyclines given to children with cancer: a systematic review [J]. Eur J Cancer,2007, 43(13) : 1959-1966.
3Tokarska-Schlattner M, Zaugg M, Zuppinger C, et al. New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics [J].J Mol Cell Cardiol, 2006, 41 (3) : 389-405.
4Yoon HR, Hong YM, Boriack RL, et al. Effect of L-carnitine supplementation on cardiac carnitine palmitoyhransferase activities and plasma carnitine concentrations in adriamycin-treated rats [J]. Pediatric Res,2003,53 (5): 788-792.
5Bryant J, Picot J, Levitt G, et al. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review [J]. Health Technol Assess, 2007,11 (27) : 1-84.
6Iarussi D, Indolfi P, Casale F, et al. Anthracycline- induced cardiotoxicity in children with cancer: strategies for prevention and management [J ]. Pediatr Drugs,2005, 7 (2) :67-76.
7Delaney CE, Hopkins SP, Addison CL. Supplementation with L-caruitine does not reduce the efficacy of epirubicin treatment in breast cancer cells [J]. Cancer Lett,2007, 252(2) : 195-207.
